Skip to content

Study · Animal study (in vivo) · horse · 2000

4 results

The effect of oxytocin on contractility of the equine oesophagus: a potential treatment for oesophageal obstruction.

Meyer GA, Rashmir-Raven A, Helms RJ, Brashier M

Equine veterinary journal1 Mar 2000Cited by 6 (Europe PMC)

PMID10743971 (opens in a new tab)DOI10.2746/042516400777591660 (opens in a new tab)PepBankPUB-10743971
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In healthy horses, intravenous oxytocin at 0.11 iu/kg caused a short-term, statistically significant relaxation of the oesophageal musculature.

    In plain wordsIn horses, a low intravenous dose of oxytocin briefly relaxed the muscles of the gullet.

    Peptide
    Oxytocin
    Outcome
    DecreaseOesophageal musculature relaxation, 0.11 iu/kg
    Study

    horsen = 9

    equine oesophagus, nasogastric tube cuff pressures
    Comparator
    Saline
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    0.11 iu/kg bwt · intravenousAs given in this study (horse).

    Source sentences

    Summary
    Administration of oxytocin i.v. at 0.11 and 0.22 iu/kg bwt, resulted in a short-term statistically significant relaxation of the musculature of the equine oesophagus.
    3 context sentences
    Summary · context
    This study was performed to determine the effect of administration of i.v. oxytocin on the contractility of the musculature associated with the equine oesophagus.
    Summary · context
    Nine clinically normal horses were fitted with a nasogastric tube modified with inflatable latex cuffs.
    Summary · context
    Oxytocin in 3 different doses or saline controls were administered i.v. in a randomised block pattern.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In healthy horses, intravenous oxytocin at 0.22 iu/kg caused a short-term, statistically significant relaxation of the oesophageal musculature.

    In plain wordsIn horses, a higher intravenous dose of oxytocin briefly relaxed the muscles of the gullet.

    Peptide
    Oxytocin
    Outcome
    DecreaseOesophageal musculature relaxation, 0.22 iu/kg
    Study

    horsen = 9

    equine oesophagus, nasogastric tube cuff pressures
    Comparator
    Saline
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    0.22 iu/kg bwt · intravenousAs given in this study (horse).

    Source sentences

    Summary
    Administration of oxytocin i.v. at 0.11 and 0.22 iu/kg bwt, resulted in a short-term statistically significant relaxation of the musculature of the equine oesophagus.
    3 context sentences
    Summary · context
    This study was performed to determine the effect of administration of i.v. oxytocin on the contractility of the musculature associated with the equine oesophagus.
    Summary · context
    Nine clinically normal horses were fitted with a nasogastric tube modified with inflatable latex cuffs.
    Summary · context
    Oxytocin in 3 different doses or saline controls were administered i.v. in a randomised block pattern.
  3. 03AnimalAnimal study (in vivo)Safety outcome

    In healthy horses, intravenous oxytocin at 0.11, 0.22 and 0.44 iu/kg caused no clinically significant cardiovascular changes.

    In plain wordsIn horses, intravenous oxytocin at three doses caused no clinically significant heart or blood pressure changes.

    Peptide
    Oxytocin
    Outcome
    No significant changeCardiovascular changes
    Study

    horsen = 9

    equine oesophagus, nasogastric tube cuff pressures
    Comparator
    Saline
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    0.11, 0.22 and 0.44 iu/kg bwt · intravenousAs given in this study (horse).

    Source sentences

    Summary
    When oxytocin was administered at 0.11, 0.22 and 0.44 iu/kg bwt, no clinically significant cardiovascular changes were seen.
    3 context sentences
    Summary · context
    This study was performed to determine the effect of administration of i.v. oxytocin on the contractility of the musculature associated with the equine oesophagus.
    Summary · context
    Nine clinically normal horses were fitted with a nasogastric tube modified with inflatable latex cuffs.
    Summary · context
    Oxytocin in 3 different doses or saline controls were administered i.v. in a randomised block pattern.
  4. 04AnimalAnimal study (in vivo)Safety outcome

    In healthy horses, signs of mild short-term abdominal discomfort followed about 5% of oxytocin administrations.

    In plain wordsIn horses, about 5% of oxytocin doses were followed by mild, short abdominal discomfort.

    Peptide
    Oxytocin
    Outcome
    Not applicableMild abdominal discomfort
    Study

    horsen = 9

    equine oesophagus, nasogastric tube cuff pressures
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · intravenousAs given in this study (horse).

    Measurements

    Mild short-term abdominal discomfort
    ≈ 5%
    oxytocin administrations

    Source sentences

    Summary
    In approximately 5% of the oxytocin administrations, signs of mild short-term abdominal discomfort were observed.
    3 context sentences
    Summary · context
    This study was performed to determine the effect of administration of i.v. oxytocin on the contractility of the musculature associated with the equine oesophagus.
    Summary · context
    Nine clinically normal horses were fitted with a nasogastric tube modified with inflatable latex cuffs.
    Summary · context
    Oxytocin in 3 different doses or saline controls were administered i.v. in a randomised block pattern.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:51 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.